Blog · corpus.blog/blogs/maps.org/posts
maps.org
maps.org
2026
25 Aug 2026
10 Aug 2026
31 Jul 2026
30 Jun 2026
Psychedelic Science 2027 Speaker Submission Invites the Field to Bridge Promise and Practiceoriginal ↗
25 Jun 2026
MAPS Publishes First-of-Its-Kind Literature Review on Psychedelic Healing for People Impacted by the Criminal Legal Systemoriginal ↗
2 Jun 2026
14 May 2026
MAPS & State of Colorado Partner to Deliver Free Harm Reduction Training for First Respondersoriginal ↗
5 May 2026
27 Apr 2026
18 Apr 2026
MAPS, in Partnership with the Shulgin Foundation, Launches Music Is the Bridge Video Series; First Episode Features Reggie Watts and Hamilton Morrisoriginal ↗
11 Mar 2026
In a Defining Election Year, MAPS Releases Policy Guidebook to Shape the Future of Psychedelic Reformoriginal ↗
5 Feb 2026
MAPS and Columbia University Partner on First-of-its-Kind Study of MDMA-Assisted Couples Therapyoriginal ↗
3 Feb 2026
13 Jan 2026
2025
MAPS Supports Therapy Education for First-Ever Department of Defense-Affiliated MDMA-Assisted Therapy Pilotoriginal ↗
23 Dec 2025
Ohio State’s Center for Psychedelic Drug Research and Education collaborates with MAPS for the Ohio P.E.A.C.E. programoriginal ↗
17 Nov 2025
14 Oct 2025
8 Oct 2025
MAPS Board of Directors Names Betty Aldworth and Ismail Lourido Ali as Co-Executive Directorsoriginal ↗
9 Sept 2025
MAPS Statement on FDA’s Public Release of Complete Response Letter for MDMA-assisted Therapyoriginal ↗
5 Sept 2025
MAPS Urges Action: Open Letter to HHS Secretary and FDA Commissioner One Year After FDA Denial of MDMA-Assisted Therapy for PTSDoriginal ↗
14 Aug 2025
Following Psychedelic Science 2025 Success, MAPS Publishes First of Hundreds of Conference Session Videosoriginal ↗
16 Jul 2025
Plant Medicine Track at Psychedelic Science 2025 Spotlights Ancestral Wisdom, Indigenous Sovereignty, and Being in Right Relationshiporiginal ↗
12 Jun 2025
Sound, Spirit, and Celebration: Maejor, Jim James, and Vic Mensa Lead the Musical Heartbeat of Psychedelic Science 2025original ↗
4 Jun 2025
Legislators, Advocates, Lawyers, and Organizers Take the Stage during Policy Track at Psychedelic Science 2025 to Shape the Future of Psychedelic Reformoriginal ↗
30 May 2025
Leaders in Psychiatry, Psychology, and Social Work to Take the Keynote Stage at Psychedelic Science 2025original ↗
29 May 2025
28 May 2025
18 Apr 2025
MAPS Announces MDMA-Assisted Therapy Education Event For Ukrainian Mental Health Practitionersoriginal ↗
15 Apr 2025
Psychedelic Science 2025 Announces Select Speakers for the Leading Conference on Psychedelic Research, Policy, and Thought Leadershiporiginal ↗
7 Mar 2025
MAPS Announces Search for New Executive Director as it Doubles Down on Advocacy and Movement Buildingoriginal ↗
12 Feb 2025
MAPS Submits Cannabis Data Safety Update Report 2024 and Protocol Amendment to FDA on Phase 2 Study of Smoked Cannabis for Veterans with PTSD (MJP2)original ↗
15 Jan 2025
2024
MAPS cleared to proceed by FDA on Phase 2 Study of Smoked Cannabis for Veterans with PTSD (MJP2)original ↗
7 Nov 2024
22 Oct 2024
MAPS submits sixth Clinical Hold Response to FDA on Phase 2 Study of Cannabis for Veterans with PTSD (MJP2)original ↗
10 Oct 2024
MAPS achieves agreement on three key points despite “Appeal Denied” letter received from FDA on Phase 2 Study of Cannabis for Veterans with PTSD (MJP2)original ↗
19 Sept 2024
MAPS Submits Formal Dispute Resolution Request Against FDA’s Clinical Hold on Phase 2 Study of Cannabis for Veterans with PTSD (MJP2)original ↗
23 Aug 2024
MAPS Statement on FDA Complete Response Letter on MDMA-Assisted Therapy for PTSD New Drug Applicationoriginal ↗
10 Aug 2024
22 Jul 2024
18 Jul 2024
12 Jul 2024
6 Jun 2024
29 May 2024
MAPS Provides Psychedelic Crisis Assessment and Intervention Training to Denver’s First Respondersoriginal ↗
11 Mar 2024
Psychedelic Science 2025 – the Fifth and Largest Psychedelic Conference in History – Announced for June 16-20 2025 in Denver, Coloradooriginal ↗
13 Feb 2024
MAPS Congratulates Lykos Therapeutics on Acceptance of New Drug Application for MDMA-Assisted Therapy for PTSDoriginal ↗
9 Feb 2024
5 Feb 2024
MAPS Unveils Improved Fiscal Sponsorship Program, Empowering Innovators in the Psychedelic Movementoriginal ↗
16 Jan 2024
MAPS Submits Cannabis Data Safety Update Report 2023 to FDA on Phase 2 Study of Smoked Cannabis for Veterans with PTSD (MJP2)original ↗
11 Jan 2024
2023
29 Dec 2023
MAPS Celebrates Submission of New Drug Application to FDA for MDMA-Assisted Therapy for PTSDoriginal ↗
13 Dec 2023
4 Dec 2023
MAPS Submits Complete Response to FDA’s Clinical Hold on Phase 2 Study of Cannabis for Veterans with PTSD (MJP2)original ↗
30 Nov 2023
The Virtual Trip Showcases Veterans Sessions from Psychedelic Science 2023 in Honor of Veterans Dayoriginal ↗
11 Nov 2023
PS2023: The Virtual Trip Unveils Latest Video Release Featuring Michael Pollan, Melissa Etheridge, and Moreoriginal ↗
9 Oct 2023
MAPS PBC Publishes Results of Successful Confirmatory Phase 3 Trial of MDMA-Assisted Therapy for PTSDoriginal ↗
13 Sept 2023
30 Aug 2023
FDA Division of Pulmonology, Allergy, and Critical Care Provides Additional Guidance on Phase 2 Study of Cannabis for Veterans with PTSD (MJP2)original ↗
11 Aug 2023
FDA Sends the Official Minutes of Type A Meeting for Phase 2 Study of Cannabis for Veterans with PTSD (MJP2)original ↗
12 Jul 2023
10 Jun 2023
MAPS-Sponsored Global Psychedelic Survey Gathers Data for a Crucial View into Psychedelic Use original ↗
22 May 2023